Beyond Comfort in Local Anesthesia: Clinical Safety and Pharmacological Limitations

The "stepwise local anesthesia technique" and multidimensional comfort strategies recently introduced in Aesthetic Plastic Surgery by Fang et al. and Gao et al. While these pharmacological, operative, and psychological synergies represent a significant advancement in patient experience, their clinical implementation-particularly in office-based and pediatric settings-demands a rigorous adherence to safety protocols and pharmacological boundaries. A primary concern is the additive toxicity of amide-type anesthetic combinations, such as lidocaine and ropivacaine. Local anesthetic systemic toxicity (LAST) presents not only through central nervous system symptoms like tinnitus and seizures but also through life-threatening cardiovascular collapse characterized by myocardial sodium channel blockade and negative inotropy. Consequently, strict adherence to weight-based dosing limits and the immediate availability of 20% lipid emulsion for resuscitation are non-negotiable standards of care. Furthermore, the selection of adjuvants must be judiciously individualized. While dexmedetomidine prolongs analgesia, it carries a risk of dose-dependent bradycardia; conversely, ketamine may induce tachycardia and increased secretions. In the context of office-based surgery, dexamethasone emerges as a superior alternative for non-diabetic patients due to its favorable systemic safety profile. Additionally, neutralizing anesthetic acidity with 8.4% sodium bicarbonate (1:10 ratio) is essential for mitigating injection pain. Finally, practitioners must account for the bimodal compliance of pediatric patients, where those aged 9 months to 6 years often require advanced sedation or general anesthesia to ensure procedural safety. In conclusion, the clinical success of "comfortable anesthesia" depends on integrating technical innovations with a meticulous commitment to toxicity prevention and evidence-based adjuvant selection.